Standout Papers

Eczema Prevalence in the United States: Data from the 2003 National Survey of Children's Health... 2010 2026 2015 2020 545
  1. Eczema Prevalence in the United States: Data from the 2003 National Survey of Children's Health (2010)
    Tatyana Shaw, Caroline Koudelka et al. Journal of Investigative Dermatology
  2. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention (2014)
    Eric L. Simpson, Joanne R Chalmers et al. Journal of Allergy and Clinical Immunology
  3. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults (2016)
    Amy S. Paller, Wynnis L. Tom et al. Journal of the American Academy of Dermatology
  4. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials (2021)
    Emma Guttman‐Yassky, Henrique D. Teixeira et al. The Lancet
  5. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial (2020)
    Eric L. Simpson, Rodney Sinclair et al. The Lancet
  6. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis (2021)
    Andrew Blauvelt, Henrique D. Teixeira et al. JAMA Dermatology
  7. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis (2021)
    Thomas Bieber, Eric L. Simpson et al. New England Journal of Medicine
  8. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis (2020)
    Jonathan I. Silverberg, Eric L. Simpson et al. JAMA Dermatology
  9. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis (2020)
    Emma Guttman‐Yassky, Andrew Blauvelt et al. JAMA Dermatology
  10. Atopic dermatitis in the pediatric population (2021)
    Jonathan I. Silverberg, S. Barbarot et al. Annals of Allergy Asthma & Immunology
  11. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies (2021)
    Kim Papp, Jacek C. Szepietowski et al. Journal of the American Academy of Dermatology
  12. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis (2023)
    Jonathan I. Silverberg, Emma Guttman‐Yassky et al. New England Journal of Medicine
  13. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis (2022)
    Eric L. Simpson, Kim Papp et al. JAMA Dermatology

Immediate Impact

13 from Science/Nature 114 standout
Sub-graph 1 of 18

Citing Papers

Remibrutinib in Chronic Spontaneous Urticaria
2025 Standout
Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps
2025 Standout
2 intermediate papers

Works of Eric L. Simpson being referenced

Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial
2019
Strategies used for measuring long-term control in atopic dermatitis trials: A systematic review
2016
and 1 more

Author Peers

Author Last Decade Papers Cites
Eric L. Simpson 8784 6751 3055 325 10.3k
Lawrence F. Eichenfield 8376 5100 2007 432 11.5k
Andreas Wollenberg 8177 5885 2724 315 11.5k
Eric L. Simpson 5873 4722 2592 141 6.9k
Thomas Werfel 7830 6264 3344 281 12.0k
Peter Schmid‐Grendelmeier 4241 4310 2561 210 8.5k
Marjolein de Bruin‐Weller 5132 4030 2105 199 6.0k
Michael J. Cork 5456 3454 1339 209 8.2k
Stephan Weidinger 7818 5832 3440 258 12.1k
Mark Boguniewicz 12990 9811 4649 221 16.1k
Mette Deleuran 4133 3243 1413 176 5.6k

All Works

Loading papers...

Rankless by CCL
2026